Answers are grounded in this paper and cite their sources.
The cytology community has long been at the leading edge of quality assurance and quality control in anatomic pathology. However, with the increasing burden of clinical care, daily operations, and regulatory compliance, quality management risks becoming just another box to check on a long list of onerous tasks. To begin to address these issues, this article will focus primarily on “proactive” quality improvement, covering quality metric selection and monitoring, and outlines how to determine when to act on data outliers.
No takes yet. Share an insight, caveat, or question.
Heher et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: